

Connecticut Insurance Department



**2022 Pharmacy Benefit Manager Rebate Report
Submitted To the Insurance & Real Estate Committee
In accordance with CGS §38a-479ppp**

March 3, 2022

Pursuant to Connecticut General Statute §38a-479ppp, the Connecticut Insurance Department has provided our 2022 Pharmacy Benefit Manager (PBM) Rebate Report.

The report summarizes Connecticut PBM rebates for calendar 2020 and 2021 as follows:

1. The aggregate dollar amount of all rebates concerning drug formularies used by such health carriers that such manager collected from pharmaceutical manufacturers that manufactured outpatient prescription drugs that were covered by such health carriers during such calendar year and are attributable to patient utilization of such drugs during such calendar year.
2. The aggregate dollar amount of all rebates, excluding any portion of the rebates received by such health carriers (i.e., the aggregate amount of the rebates in part 1 that are retained by the PBM), concerning drug formularies that such manager collected from pharmaceutical manufacturers that manufactured outpatient prescription drugs that were covered by such health carriers during such calendar year and attributable to patient utilization of such drugs by covered persons under such health care plans during such calendar year.

The Department compiled the report with data collected from 7 entities and the results are described on the following pages. Please note, this data only represents the PBM rebates for the fully insured market.

We hope you find this report informative.

Respectfully,

A handwritten signature in blue ink, appearing to read 'Andrew N. Mais', with a stylized flourish at the end.

Andrew N. Mais Insurance Commissioner

1. The aggregate dollar amount of all rebates concerning drug formularies used by such health carriers that such manager collected from pharmaceutical manufacturers that manufactured outpatient prescription drugs that were covered by such health carriers during such calendar year and are attributable to patient utilization of such drugs during such calendar year.

For Calendar Year 2020: \$162,157,586

For Calendar Year 2021: \$327,230,908

2. The aggregate dollar amount of all rebates, excluding any portion of the rebates received by such health carriers (i.e., the aggregate amount of the rebates in part 1 that are retained by the PBM), concerning drug formularies that such manager collected from pharmaceutical manufacturers that manufactured outpatient prescription drugs that were covered by such health carriers during such calendar year and attributable to patient utilization of such drugs by covered persons under such health care plans during such calendar year.

\$4,972,846 (3.1%)

For Calendar Year 2020: \$23,315,521  (14.4%)

For Calendar Year 2021: \$24,009,613 (7.3%)

\$2,511,067 (0.8%)

3.1%

In calendar year 2020, PBMs in aggregate, retained 14.4% of all pharmaceutical manufacturer rebates they collected, while in calendar year 2021, in aggregate, they retained 7.3% of all pharmaceutical rebates they collected.

0.8%